Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies. Previously, we established, in a direct xenograft model...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bhatt, Shruti, Ashlock, Brittany M., Toomey, Ngoc L., Diaz, Luis A., Mesri, Enrique A., Lossos, Izidore S., Ramos, Juan Carlos
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668825/
https://ncbi.nlm.nih.gov/pubmed/23635777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI64503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars